特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

狂犬病ワクチンの世界市場:成長、動向、および予測

Rabies Vaccine Market - Growth, Trends, and Forecasts (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 704728
出版日 ページ情報 英文 114 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.98円で換算しております。
狂犬病ワクチンの世界市場:成長、動向、および予測 Rabies Vaccine Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日: 2020年06月01日 ページ情報: 英文 114 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートは世界の狂犬病ワクチン市場について調査しており、市場機会や課題、成長および阻害要因、製品タイプ・ワクチンタイプ・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の仮定
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 成長要因
  • 阻害要因
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメント

  • 製品タイプ別
  • 予防接種タイプ別
    • 暴露前予防接種(PEV)
    • 暴露後予防接種(PEP)
  • エンドユーザー別
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • AstraZeneca (MedImmune)
    • Berna Biotech Ltd
    • GlaxoSmithKline
    • Merck & Co Inc
    • Novartis AG
    • Pfizer Inc
    • Sanofi Pasteur, Inc
    • Zoetis Animal Healthcare
    • *リストは例示列挙です。

第7章 市場機会および将来動向

目次
Product Code: 62883

Rabies is a viral disease spread by the bite or scratch of an animal, however, the symptoms appear relatively slowly. In such cases, by the time, the symptoms appear, it is generally too late to save the patients. In the developed markets, the cases of human rabies are less because of more pet-friendly communities and government initiatives, however, in emerging markets as well as low-income countries, there are fewer regulations to protect the people against animals bites and a large number of stray dogs can be observed across metropolitan cities as well as other cities and towns. Such factors raise concerns regarding low protection against dog bites which raises the demand for rabies vaccines in such regions. However, limited resources, as well as negligence by government general public, are among the major causes which limit the use and adoption of rabies vaccines.

Key Market Trends

The Purified Chick Embryo Cell Rabies Vaccine is Expected to Show Better Growth

The purified chick embryo cell vaccine is used to protect people from post-exposure or pre-exposure. The veterinarians who are in contact with animals, such as cats, dogs, foxes, skunks, raccoons, bobcats, coyotes, and bats are more likely to be exposed to the rabies virus, leading to rising cases of rabies. Purified chick embryo cell rabies vaccines are prepared with the help of primary chick embryo cells derived from specific pathogen-free (SPF) eggs. It consists of purified and concentrated rabies virus antigen, inactivated with B-propiolactone. This vaccine acts by exposing a small dose of rabies virus to the patient in order to develop immunity to the disease. This vaccine can be used for post-exposure or pre-exposure. Such factors drive its importance and usage across hospitals and clinics.

North America is Estimated to Have Largest Share in the Global Market

According to the data published by Centers for Disease Control and Prevention (CDC) in the United States, wild animals accounted for 92.4% of the rabies cases, whereas domestic animals accounted for 48.7% cases of rabies. In the past few years the number of human deaths attributed to rabies in the United States has declined due to two major reasons, first one is animal control and vaccination programs. Secondly, effective human rabies vaccines and immunoglobulins have been developed over time. Similarly major steps were taken across Canada and Mexico to protect the animals and humans rabies virus infection spread. Significant contribution by government and companies interests in this regions, makes this region, highly useful in terms of demand and use of rabies vaccines.

Competitive Landscape

The major market players are focusing on technological advancements and pet care initiatives in collabroation with hospitals and government channels. Some of the major players in the market are Zoetis Inc., Merck & Co Inc, Sanofi SA, Elanco, Virbac, etc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Mortality due to Rabies
    • 4.2.2 Large Population of Stray Dogs in Low and Middle Income Countries
    • 4.2.3 Growing Pet Management technological Advancements and Services
  • 4.3 Market Restraints
    • 4.3.1 Low Immunization Rates in Dogs
    • 4.3.2 Lack of Awareness and Negligence by Government and Public
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Baby Hamster Kidney (BHK)
    • 5.1.2 Purified Chick Embryo Cell Rabies Vaccine
    • 5.1.3 Vero Cell Rabies Vaccine
    • 5.1.4 Other Product Types
  • 5.2 By Vaccination Type
    • 5.2.1 Pre-Exposure Vaccination (PEV)
    • 5.2.2 Post-Exposure Prophylaxis (PEP)
  • 5.3 By End-User
    • 5.3.1 Animals
    • 5.3.2 Humans
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 France
      • 5.4.2.2 Germany
      • 5.4.2.3 United Kingdom
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Berna Biotech Ltd
    • 6.1.2 GlaxoSmithKline plc
    • 6.1.3 Merck & Co Inc
    • 6.1.4 Novartis International AG
    • 6.1.5 Pfizer Inc
    • 6.1.6 Sanofi SA
    • 6.1.7 Zoetis Inc.
    • 6.1.8 Elanco
    • 6.1.9 Virbac

7 MARKET OPPORTUNITIES AND FUTURE TRENDS